rs193922916 — APP A673V (Aβ A2V)

APP A673V — The Recessive Mutation That Is Both Pathogenic and Protective

The amyloid precursor protein (APP) gene encodes a large transmembrane protein whose sequential cleavage by beta-secretase (BACE1)¹¹ beta-secretase (BACE1)
The enzyme that makes the first cut in APP, releasing the C99 fragment that is subsequently cleaved by gamma-secretase to produce amyloid-beta peptides and gamma-secretase generates the amyloid-beta (Aβ) peptides central to Alzheimer's disease pathology. Most pathogenic APP mutations cluster around the cleavage sites and accelerate Aβ production; most operate via autosomal dominant inheritance.

The A673V variant is an exception on both counts. Discovered in 2009 in an Italian family by Di Fede et al.²² Di Fede et al.
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323:1473–7, A673V follows strict autosomal recessive inheritance — disease occurs only when both APP copies carry the mutation. Heterozygous relatives who carry a single copy remain cognitively unaffected. This unusual pattern arises because the mutant Aβ peptide interferes with the aggregation of normal wild-type Aβ, creating a dominant-negative protective effect that is lost when no wild-type peptide is present (i.e., in homozygotes).

The Mechanism

Position 673 in the APP protein (position 2 in the Aβ peptide, hence the alternative designation Aβ A2V) sits immediately adjacent to the BACE1 beta-secretase cleavage site. The A673V substitution changes an alanine to a valine at this critical junction, with two consequences that differ dramatically based on gene dosage.

In the homozygous state, Zhang et al. 2017³³ Zhang et al. 2017
BACE1 Cleavage Site Selection Critical for Amyloidogenesis. J Neurosci 2017;37:6915–25 showed that A673V shifts BACE1 preferential cleavage from the Glu11 site to the Asp1 site, markedly elevating the amyloidogenic C99/C89 ratio and driving excess Aβ production. The mutant A2V-Aβ peptide then forms oligomers with a distinctive polymer-network morphology — connecting hydrophobic residues on external surfaces — that is more aggregation-prone than wild-type, leading to accelerated fibrillization and neurotoxicity.

In the heterozygous state, something remarkable occurs: when A2V-mutant and wild-type Aβ peptides co-exist, Messa et al. 2014⁴⁴ Messa et al. 2014
J Biol Chem 2014;289:24143–52 demonstrated that the mixed assemblies form structures nearly identical to wild-type aggregates, but with slower kinetics (characteristic time τ = 3 hours versus 1.5 hours for pure A2V and 6.7 hours for wild-type). Di Fede et al. showed that co-incubation "conferred instability on Aβ aggregates and inhibited amyloidogenesis and neurotoxicity," explaining why one normal APP allele fully protects carriers despite the presence of the pathogenic A2V peptide.

The neuropathological fingerprint is distinctive. Giaccone et al. 2010⁵⁵ Giaccone et al. 2010
Acta Neuropathol 2010;120:803–12 documented extensive amyloid deposition in homozygous brain tissue with an atypical topographic pattern: cerebellar involvement was pronounced and the striatum was relatively spared — the opposite of the hierarchical spread seen in sporadic Alzheimer's disease. Cerebrovascular amyloid deposition was particularly prominent.

The Evidence

The original Di Fede et al. 2009 Science paper⁶⁶ Di Fede et al. 2009 Science paper identified A673V in a proband with early-onset Alzheimer-type dementia and her younger sister showing initial cognitive decline — both homozygous. Multiple heterozygous relatives in the same family were examined and found to be cognitively unaffected, establishing the recessive Mendelian pattern.

The variant is vanishingly rare: the A allele was not observed in any of 478 alleles in the ALFA database. It appears primarily in Italian families, with only a handful of homozygous cases documented in the world literature. ClinVar (variation ID 18106) classifies it as pathogenic for Alzheimer disease based on OMIM-curated evidence (SCV000040032.2).

The dominant-negative anti-amyloidogenic effect of the heterozygous state has inspired a therapeutic direction. Cimini et al. 2016⁷⁷ Cimini et al. 2016 developed a cell-permeable fusion peptide (Aβ1-6A2VTAT(D)) that mimics the heterozygous protective state, showing reversal of Aβ1-42-induced synaptopathy in both cell culture and mouse models. This line of research remains in early-stage preclinical development.

Practical Actions

For heterozygous carriers (AG genotype): the recessive mechanism means your single A allele does not elevate your personal Alzheimer's risk above population baseline. The clinical relevance is entirely reproductive — two carrier parents have a 25% chance per pregnancy of producing a homozygous child. Genetic counselling before conceiving and partner testing resolve the actual risk.

For homozygous individuals (AA genotype): this is a severe early-onset Alzheimer's disease genotype. Cognitive and neurological assessment with a specialist in neurodegenerative disease is indicated immediately. Clinical genetic counselling for the individual and family members is essential.

Interactions

The most important clinical interaction at this locus is the contrast with rs63750847 (APP A673T, the Icelandic protective variant). Both variants affect the identical codon — A673T substitutes threonine and is associated with ~50% reduced Alzheimer's risk, while A673V substitutes valine and causes recessive disease. The opposing consequences of two different substitutions at the same nucleotide position illustrate how precisely BACE1 substrate recognition can be tuned by single amino acid changes.

APOE4 (rs429358) modifies risk for sporadic Alzheimer's disease and could theoretically act as a modifier for the rate or severity of amyloid accumulation in the unusual context of a homozygous A673V carrier, though no direct clinical data on this compound situation exists given the extreme rarity of A673V homozygotes.